After presenting encouraging preclinical results in January — demonstrating highly valuable clinical benefits — Sangair AB now takes the next major step toward a new treatment for sepsis and our continued fight against antimicrobial resistance.
To further accelerate our development, the company’s headquarters in Solna are now relocating to Lund, Medicon Village. This move allows us to fully leverage the innovative ecosystem and deep regional competence, strengthening our organization and expanding the opportunities ahead for system development.
We are already experiencing the positive effects of closer collaboration with neighbouring companies and look forward to the next phase—alongside upcoming clinical results expected in the coming months.
Our clinical team and expertise remain based at Uppsala Akademiska Hospital, where we continue to benefit from the excellent clinical competence and resources available there.